“…These data are consistent with observed changes in clinical trials that target anxiety sensitivity (Schmidt, Capron, Raines, & Allan, 2014; Schmidt, Norr, Allan, Raines, & Capron, In Press). Anxiety sensitivity was evaluated in the current conceptualization of treatment response across both conditions because of the observed significant decrease in anxiety related symptoms across both conditions (Schmidt et al, 2015), and scientific evidence for change in anxiety sensitivity in the context of non-specialized treatments (such as the intervention provided for the control condition in the current study (Ablon, Levy, & Katzenstein, 2006; Barlow, 2000; Geckler, McCormack, & Goodman, 1984; McHugh et al, 2014). Participants who responded to at least one aspect of treatment (i.e., smoking abstinence or AS symptom reduction) were classified as a treatment responder.…”